Baker Bros. Advisors LP Rhythm Pharmaceuticals, Inc. Transaction History
Baker Bros. Advisors LP
- $7.9 Billion
- Q1 2024
A detailed history of Baker Bros. Advisors LP transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 6,398,365 shares of RYTM stock, worth $263 Million. This represents 3.51% of its overall portfolio holdings.
Number of Shares
6,398,365
Previous 6,398,365
-0.0%
Holding current value
$263 Million
Previous $294 Million
5.74%
% of portfolio
3.51%
Previous 3.42%
Shares
13 transactions
Others Institutions Holding RYTM
# of Institutions
176Shares Held
62.4MCall Options Held
880KPut Options Held
84.1K-
Primecap Management CO Pasadena, CA7.75MShares$318 Million0.25% of portfolio
-
Black Rock Inc. New York, NY6.53MShares$268 Million0.01% of portfolio
-
Goldman Sachs Group Inc New York, NY5.11MShares$210 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.3MShares$136 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.27MShares$134 Million2.97% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $2.29B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...